Relay Therapeutics Stock 8-Day Winning Spree: Stock Climbs 29%
Relay Therapeutics (RLAY) – a small molecule drug developer targeting oncology and genetic diseases – hit a 8-day winning streak, with cumulative gains over this period amounting to 29%. The company’s market cap has surged by about $710 Mil over the last 8 days and currently stands at $3.1 Bil.
Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
But here is the interesting part. You are reading about this 29% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Marvell Stock And The High-Stakes Forecast Behind The AI Story
- VO’s Price Tag Asks Investors To Trust The Future
- The GenAI Metric Accenture Stock Quietly Dropped Reveals A Much Bigger Bet
- MGK’s Holdings Point To A Stronger Earnings Future
- Does XOP’s History Make This Dip a Buy?
- Does IWR’s New High Demand Action?
The following table summarizes the return for RLAY stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | RLAY | S&P 500 |
|---|---|---|
| 1D | 0.9% | -1.4% |
| 8D (Current Streak) | 29.3% | 1.4% |
| 1M (21D) | 27.7% | -1.1% |
| 3M (63D) | 77.6% | 11.9% |
| YTD 2026 | 106.1% | 7.6% |
| 2025 | 105.3% | 16.4% |
| 2024 | -62.6% | 23.3% |
| 2023 | -26.3% | 24.2% |
However, big gains can follow sharp reversals – but how has RLAY behaved after prior drops? See RLAY Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 45 S&P constituents with 3 days or more of consecutive gains and 28 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 44 | 2 |
| 4D | 0 | 12 |
| 5D | 1 | 8 |
| 6D | 0 | 6 |
| 7D or more | 0 | 0 |
| Total >=3 D | 45 | 28 |
Key Financials for Relay Therapeutics (RLAY)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $10.0 Mil | $15.4 Mil |
| Operating Income | $-385.7 Mil | $-302.7 Mil |
| Net Income | $-337.7 Mil | $-276.5 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $7.0 Mil | $3.0 Mil |
| Operating Income | $-60.6 Mil | $-78.6 Mil |
| Net Income | $-54.9 Mil | $-73.3 Mil |
While RLAY stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.